Treatment Overview
Comparison of the three primary keratoconus interventions across six clinical outcome dimensions. Scores are normalized indices (0-10) derived from published clinical evidence, not direct clinical percentages.
Corneal Cross-Linking
UV-A + ribofflavin collagen stiffening. Halts progression in 92-96% of progressive eyes.
RGP Lenses
Rigid gas-permeable lenses providing 2-4 line visual improvement via tear lens effect.
Scleral Lenses
Large-diameter lenses vaulting the cornea. 3-5 line gain in moderate-to-advanced disease.
Multi-Axis Treatment Comparison
Normalized outcome scores across six clinical dimensions (0-10 scale)
Detailed Comparison
Side-by-side analysis of clinical outcomes, recovery profiles, and evidence levels for all three interventions.
Evidence-Weighted Fit Score by Disease Stage
Composite scores reflecting published outcomes by stage; not direct pooled success rates. CXL scores reflect disease stabilization, lens scores reflect visual rehabilitation. See methodology disclosure in Patient Profile section.
Outcome Dimension Scores
Normalized scores (0-10) by treatment and dimension
Patient Profile Filter
Adjust patient characteristics to see which intervention has the highest evidence-based success rate for specific clinical scenarios.
Evidence-Weighted Profile Fit — Filtered View
Profile fit scores based on selected patient characteristics (0-100 scale)
Severity Stage Reference
Amsler-Krumeich classification with recommended first-line intervention
Patient-Reported Complications
Common adverse events and complications organized by treatment. Rates reflect published incidence from clinical studies.
Treatment Cost Comparison
Out-of-pocket and insurance-covered cost estimates for each treatment. Figures reflect US market averages (2025-2026) and vary by geographic region, provider, and insurance plan. Costs shown per eye or per pair as noted.
Out-of-Pocket vs. Insurance-Covered Cost Ranges
Estimated cost ranges per treatment (USD). CXL shown per eye; lenses shown per pair. Bilateral CXL patients should multiply CXL costs by 2 for total treatment cost.
5-Year Cumulative Cost Projection
Estimated total cost over 5 years including initial treatment, replacements, and follow-up care
Cost Estimate Disclaimer
All cost figures are estimated ranges based on published data and provider surveys as of 2025-2026. Actual costs vary significantly by geographic location (major metros 20-35% higher), provider type (academic vs. private practice), insurance plan, deductible status, and individual patient needs. These estimates are for planning purposes only and do not constitute a price quote. Always verify costs and coverage with your provider and insurer before proceeding with treatment.
Insurance coverage policies change frequently. Prior authorization is typically required for CXL. Contact your insurance provider to verify current coverage, network status, and out-of-pocket responsibilities.
Other Keratoconus Treatments
This dashboard focuses on the three most common keratoconus interventions, but several other treatments play important roles in management. Patients should be aware of these options and discuss them with a cornea specialist.
Familial Risk Screening
Siblings of keratoconus patients have approximately 20x higher risk of developing keratoconus. First-degree relatives should undergo corneal tomography screening.
Clinical Terminology Glossary
Definitions of clinical terms used throughout this dashboard, intended for patients and non-specialist readers.
Evidence & Sources
Key clinical studies supporting the data presented in this dashboard. Evidence levels follow standard grading (A = multiple RCTs/systematic reviews, B = clinical series/retrospective studies).
Important Disclaimer
This dashboard is an educational tool designed to summarize published clinical evidence on keratoconus treatments. It is not a substitute for professional medical advice, diagnosis, or treatment. Treatment decisions must be made by a qualified ophthalmologist or corneal specialist based on individual patient characteristics, corneal tomography, and clinical examination.
Scores presented as normalized indices (0-10) are derived from published evidence and clinical guidelines, not direct clinical percentages. Success rates represent population-level outcomes; individual results vary. Consult your eye care provider for personalized treatment recommendations.
Data sources include peer-reviewed publications from PubMed/PMC, the Cochrane Library, and clinical evidence from published systematic reviews and randomized controlled trials. Last updated: July 2026.